The Business Research Company
The Business Research Company’s Oncology Biomarkers Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2026 /EINPresswire.com/ — “The field of oncology biomarkers is witnessing swift growth as advancements in cancer detection and personalized medicine continue to evolve. These biological indicators play a critical role in improving cancer diagnosis, treatment, and monitoring, making the market for oncology biomarkers increasingly significant. Below is a detailed overview of the market’s current status, growth drivers, regional insights, and emerging trends.
Strong Expansion Forecast for the Oncology Biomarkers Market Through 2026
The oncology biomarkers market has expanded rapidly in recent years and is set to grow from $17.3 billion in 2025 to $19.73 billion in 2026, reflecting a robust compound annual growth rate (CAGR) of 14.1%. This expansion during the historical period has been driven by the growth of cancer screening programs, advancements in molecular biology research, wider availability of biomarker testing platforms, an increase in oncology clinical trials, and strengthened collaborations between research institutions and hospitals.
Download a free sample of the oncology biomarkers market report:
Projected Market Growth and Emerging Drivers Beyond 2026
Looking ahead, the oncology biomarkers market is expected to accelerate further, reaching $33.63 billion by 2030 with an anticipated CAGR of 14.3%. Key contributors to this growth include rising demand for personalized oncology treatments, the expansion of AI-driven biomarker discovery technologies, increased investment in cancer genomics, broader adoption of liquid biopsy techniques, and a heightened focus on early cancer detection and ongoing patient monitoring. Trends likely to shape the market during this period involve greater use of precision oncology diagnostics, more frequent application of genetic and protein biomarkers, integration of bioinformatics for biomarker analysis, growth in companion diagnostic development, and an intensified emphasis on tailored cancer therapies.
Understanding Oncology Biomarkers and Their Clinical Importance
Oncology biomarkers are biological markers such as genes, proteins, or molecules that provide crucial information about the presence or progression of cancer. They are used to diagnose cancer, predict how patients will respond to treatments, and track disease progression or relapse. By analyzing these markers, clinicians can design more personalized and effective treatment plans, improving patient outcomes.
View the full oncology biomarkers market report:
The Rising Incidence of Cancer as a Key Market Driver
One of the primary forces fueling the oncology biomarkers market is the increasing global incidence of cancer. Cancer is characterized by uncontrolled cell growth that can spread to other parts of the body. Biomarkers offer vital insights about the specific type of cancer by examining genetic, protein, and other molecular factors in a patient’s body. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there will be more than 35 million new cancer cases worldwide. This represents a 77% increase compared to approximately 20 million cases estimated in 2022. Such a significant rise in cancer cases is a major factor accelerating the demand for oncology biomarker solutions.
Reading those endpoints takes some literacy of its own. National Health Underwriters explains the difference between relative and absolute risk.
North America’s Leading Position in the Oncology Biomarkers Market by 2026
In 2025, North America held the largest share of the global oncology biomarkers market. The report covers a wide range of regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, giving a broad perspective on global market dynamics.
Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: [email protected]
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company”
Oliver Guirdham
The Business Research Company
+44 7882 955267
[email protected]
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Article originally published on www.einpresswire.com as Oncology Biomarkers Market Research Explores Growth Within A $33.63 Billion Opportunity
